European Medicines Agency

European Medicines Agency. The European Medicines Agency is a decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use within the EU single market. Established to harmonize the work of existing national medicines regulatory authorities, it operates a centralized authorization procedure that provides a single marketing authorization valid across all member states. Its work ensures that all medicines available on the EU market are safe, effective, and of high quality, playing a critical role in public health protection and fostering innovation in the pharmaceutical industry.

History and establishment

The agency was formally established in 1995 following the adoption of Council Regulation (EEC) No 2309/93, with its operational activities commencing in London. Its creation was a cornerstone of the EU's efforts to complete the single market, aiming to overcome the fragmentation caused by differing national regulatory standards and to provide a streamlined pathway for innovative medicines. The foundational legal framework was significantly influenced by earlier pharmaceutical directives and the need for a robust system following the thalidomide scandal. In the wake of Brexit, the agency relocated its headquarters from London to Amsterdam in 2019, a move coordinated by the European Council.

Organization and governance

The agency is headed by an Executive Director, currently Emer Cooke, and is overseen by a Management Board composed of representatives from each member state, the European Commission, and the European Parliament. Its scientific core resides in several permanent scientific committees, most notably the Committee for Medicinal Products for Human Use and the Committee for Medicinal Products for Veterinary Use. The agency works in close collaboration with the national competent authorities in member states, which form its regulatory network, and it is funded primarily by fees from the pharmaceutical industry and a subsidy from the EU budget. Key internal directorates handle areas such as patient health protection, veterinary medicines, and data analytics.

Functions and responsibilities

Its primary function is to conduct scientific assessments of applications for marketing authorization for human and veterinary medicines through its centralized procedure, which is mandatory for certain advanced therapies and medicines derived from biotechnology. The agency is also responsible for the ongoing monitoring of medicine safety through its pharmacovigilance system, coordinating the EudraVigilance database for reporting adverse reactions. It provides scientific advice to companies, fosters innovation in areas like orphan drugs and paediatric medicines, and manages the supervision of clinical trials within the EU via the Clinical Trials Information System. Furthermore, it plays a key role in managing medicine shortages and crises.

Regulatory procedures and scientific committees

The centralized authorization procedure is the most prominent regulatory pathway managed here, resulting in a single decision by the European Commission applicable across the EU. For other medicines, the agency coordinates the decentralized and mutual recognition procedures involving national authorities. Its scientific assessments are performed by its committees, which utilize expertise from across the European Economic Area; the Pharmacovigilance Risk Assessment Committee assesses safety issues, while the Committee for Advanced Therapies evaluates innovative products like gene therapy and stem cell therapy. The agency also publishes scientific guidelines and maintains the European Union Clinical Trials Register.

Key initiatives and international cooperation

The agency has launched major initiatives such as the PRIME scheme to enhance support for promising medicines and the EU Medicines Verification System to combat falsified medicines. It is a founding member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, promoting global regulatory convergence. The agency maintains strong collaborative ties with other major regulators, including the U.S. Food and Drug Administration, Health Canada, and the World Health Organization. It also plays a pivotal role in the EU's response to public health emergencies, as demonstrated during the COVID-19 pandemic with the rapid assessment of COVID-19 vaccines and therapeutics.

Category:European Union agencies Category:Medicine regulation in Europe